Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01226732 · ClinicalTrials.gov registry record · Phase 1
A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors
A Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 3
- Study locations
NCT01226732 is a Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy that has completed, run by SCRI Development Innovations. The registered enrollment target is 23 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT01226732, a Phase 1 study of Metastatic or Unresectable Solid Tumor Malignancy, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment option, including colorectal and breast cancer.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Hsp90 Inhibitor AUY 922
Study Locations (3)
Florida
- Florida Cancer Specialists - Fort Myers
Oklahoma
- Oklahoma University - Oklahoma City
Tennessee
- Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01226732
The ClinicalTrials.gov registry entry for NCT01226732 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic or Unresectable Solid Tumor Malignancy appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT01226732 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01226732 about?
NCT01226732 is a clinical study titled "A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors". The investigators propose this Phase I trial of the combination of AUY922 and capecitabine to determine the maximum tolerated dose (MTD) in patients with advanced solid tumors. This combination treatment has potential applicability in tumor types where capecitabine or fluorouracil is a treatment opt...
What is the current status of trial NCT01226732?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-11. Estimated completion is 2014-06.
What conditions does trial NCT01226732 study?
This clinical trial studies the following conditions: Metastatic or Unresectable Solid Tumor Malignancy.
What interventions are being tested in trial NCT01226732?
The interventions under investigation include: Capecitabine (DRUG), Hsp90 Inhibitor AUY 922 (DRUG).
Who is sponsoring clinical trial NCT01226732?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01226732 being conducted?
This trial has 3 study locations across Florida, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.